Individual and combined glucose-lowering effects of glucagon receptor antagonism and dipeptidyl peptidase-4 inhibition

被引：0
|
作者：
Maagensen, H. [1 ]
Haedersdal, S. [1 ]
Lund, A. [1 ]
Nielsen-Hannerup, E. [1 ]
Holst, J. [2 ]
Knop, F. [1 ,2 ]
Vilsboll, T. [3 ,4 ]
机构：
[1] Steno Diabet Ctr Copenhagen, Clin Metab Physiol, Hellerup, Denmark
[2] Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[3] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
504
引用
收藏
页码：S246 / S247
页数：2
相关论文
共 50 条
  • [1] Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Dipeptidyl Peptidase-4 Inhibition
    Haedersdal, Sofie
    Lund, Asger B.
    Nielsen-Hannerup, Elisabeth
    Maagensen, Henrik
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES, 2018, 67
  • [2] Individual and combined glucose-lowering effects of glucagon receptor antagonism and sodium-glucose cotransporter 2 inhibition
    Haedersdal, S.
    Lund, A.
    Maagensen, H.
    Nielsen-Hannerup, E.
    Holst, J.
    Knop, F.
    Vilsboll, T.
    DIABETOLOGIA, 2018, 61 : S312 - S312
  • [3] Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition
    Haedersdal, Sofie
    Lund, Asger B.
    Maagensen, Henrik
    Nielsen-Hannerup, Elisabeth
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES, 2018, 67
  • [4] Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition
    Ahren, Bo
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (07) : 1128 - 1135
  • [5] URATE-LOWERING EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
    Panevin, Taras S.
    Zhelyabina, Olga, V
    Eliseev, Maxim S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2020, 23 (04): : 349 - 356
  • [6] Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
    John-Michael Gamble
    Jennifer R. Donnan
    Eugene Chibrikov
    Laurie K. Twells
    William K. Midodzi
    Sumit R. Majumdar
    Scientific Reports, 8
  • [7] Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
    Gamble, John-Michael
    Donnan, Jennifer R.
    Chibrikov, Eugene
    Twells, Laurie K.
    Midodzi, William K.
    Majumdar, Sumit R.
    SCIENTIFIC REPORTS, 2018, 8
  • [8] Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
    Rosenstock, J.
    Sankoh, S.
    List, J. F.
    DIABETES OBESITY & METABOLISM, 2008, 10 (05): : 376 - 386
  • [9] The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
    Avogaro, Angelo
    Fadini, Gian Paolo
    DIABETES CARE, 2014, 37 (10) : 2884 - 2894
  • [10] Enhanced glucose-lowering effect of dipeptidyl peptidase-4 inhibitor in subjects with type 2 diabetes who have a history of gastrectomy
    Wada, Y.
    Hamamoto, Y.
    Honjo, S.
    Fujimoto, K.
    Tatsuoka, H.
    Matsuoka, A.
    Ikeda, H.
    Fujikawa, J.
    Koshiyama, H.
    DIABETOLOGIA, 2014, 57 : S359 - S360
12345